A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma
DOI:
https://doi.org/10.2340/actadv.v102.1062Keywords:
Sézary syndrome, programmed-death 1, erythrodermic mycosis fungoides, erythrodermic psoriasis, erythrodermic eczema, erythrodermic drug-induced erythroderma, programmed cell death protein 1Abstract
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with erythroderma, 21 were diagnosed with eczema, 17 with psoriasis, 20 with drug-induced erythroderma, 13 with erythrodermic mycosis fungoides and 20 with Sézary syndrome. Nail alterations, ear involvement, and severe scaling were significantly associated with psoriasis (p = 0.044). Fever and hypereosinophilia were associated with drug-induced erythroderma. Expression of programmed cell death protein 1 was observed in all skin biopsies. However, with Sézary syndrome, programmed cell death protein 1 expression was significantly higher than with other aetiologies. A programmed cell death protein 1 hormone receptor score (H-score) >50 was associated with Sézary syndrome (p < 0.001, sensitivity 75%, specificity 92%) as well as CXCL13 expression (p < 0.044). CD7 loss was more frequent with erythrodermic mycosis fungoides and Sézary syndrome (p = 0.022). This study reports the importance of programmed cell death protein 1 expression for the differential diagnosis of Sézary syndrome and other aetiologies, including erythrodermic mycosis fungoides.
Downloads
References
Botella-Estrada R. Erythroderma. A clinicopathological study of 56 cases. Arch Dermatol 1994; 130: 1503-1507. DOI: https://doi.org/10.1001/archderm.130.12.1503
https://doi.org/10.1001/archderm.1994.01690120039004 DOI: https://doi.org/10.1001/archderm.1994.01690120039004
Yuan X-Y, Guo J-Y, Dang Y-P, Qiao L, Liu W. Erythroderma: a clinical-etiological study of 82 cases. Eur J Dermatol 2010; 20: 373-377.
https://doi.org/10.1684/ejd.2010.0943 DOI: https://doi.org/10.1684/ejd.2010.0943
Li J, Zheng H-Y. Erythroderma: a clinical and prognostic study. Dermatology 2012; 225: 154-162.
https://doi.org/10.1159/000342365 DOI: https://doi.org/10.1159/000342365
Khaled A, Sellami A, Fazaa B, Kharfi M, Zeglaoui F, Kamoun M. Acquired erythroderma in adults: a clinical and prognostic study: acquired erythroderma in adults. J Eur Acad Dermatol Venereol 2009; 24: 781-788.
https://doi.org/10.1111/j.1468-3083.2009.03526.x DOI: https://doi.org/10.1111/j.1468-3083.2009.03526.x
Miyashiro D, Sanches JA. Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Sci Rep 2020; 10: 9774.
https://doi.org/10.1038/s41598-020-66040-7 DOI: https://doi.org/10.1038/s41598-020-66040-7
César A, Cruz M, Mota A, Azevedo F. Erythroderma. A clinical and etiological study of 103 patients. J Dermatol Case Rep 2016; 10: 1-9.
https://doi.org/10.3315/jdcr.2016.1222 DOI: https://doi.org/10.3315/jdcr.2016.1222
Zip C, Murray S, Walsh NMG. The specificity of histopathology in erythroderma. J Cutan Pathol 1993; 20: 393-398.
https://doi.org/10.1111/j.1600-0560.1993.tb00660.x DOI: https://doi.org/10.1111/j.1600-0560.1993.tb00660.x
Ram-Wolff C, Martin-Garcia N, Bensussan A, Bagot M, Ortonne N. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am J Dermatopathol 2010; 32: 755-763.
https://doi.org/10.1097/DAD.0b013e3181cfbfbf DOI: https://doi.org/10.1097/DAD.0b013e3181cfbfbf
Kamarashev J, Burg G, Kempf W, Schmid MH, Dummer R. Comparative analysis of histologicai and immunohistological features in mycosis fungoides and Sezary syndrome. J Cutan Pathol 1998; 25: 407-412.
https://doi.org/10.1111/j.1600-0560.1998.tb01766.x DOI: https://doi.org/10.1111/j.1600-0560.1998.tb01766.x
Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, et al. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. Br J Dermatol 2015; 173: 93-105.
https://doi.org/10.1111/bjd.13832 DOI: https://doi.org/10.1111/bjd.13832
Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-1714.
https://doi.org/10.1182/blood-2018-11-881268 DOI: https://doi.org/10.1182/blood-2018-11-881268
Walsh NMG, Prokopetz R, Tron VA, Sawyer DM, Kevin Walters A, Murray S, et al. Histopathology in erythroderma: review of a series of cases by multiple observers. J Cutan Pathol 1994; 21: 419-423.
https://doi.org/10.1111/j.1600-0560.1994.tb00283.x DOI: https://doi.org/10.1111/j.1600-0560.1994.tb00283.x
Mangold AR, Thompson AK, Davis MD, Saulite I, Cozzio A, Guenova E, et al. Early clinical manifestations of Sézary syndrome: a multicenter retrospective cohort study. J Am Acad Dermatol 2017; 77: 719-727.
https://doi.org/10.1016/j.jaad.2017.05.036 DOI: https://doi.org/10.1016/j.jaad.2017.05.036
Samimi S, Benoit B, Evans K, Wherry EJ, Showe L, Wysocka M, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 2010; 146: 1382.
https://doi.org/10.1001/archdermatol.2010.200 DOI: https://doi.org/10.1001/archdermatol.2010.200
Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Ann Diagn Pathol 2017; 28: 54-59.
https://doi.org/10.1016/j.anndiagpath.2017.02.003 DOI: https://doi.org/10.1016/j.anndiagpath.2017.02.003
Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol 2012; 34: 126-128.
https://doi.org/10.1097/DAD.0b013e31821c35cb DOI: https://doi.org/10.1097/DAD.0b013e31821c35cb
Çetinözman F, Jansen PM, Vermeer MH, Willemze R. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol 2012; 148: 1379.
https://doi.org/10.1001/archdermatol.2012.2089 DOI: https://doi.org/10.1001/archdermatol.2012.2089
Çetinözman F, Jansen PM, Willemze R. Expression of programmed death-1 in skin biopsies of benign inflammatory vs. lymphomatous erythroderma. Br J Dermatol 2014; 171: 499-504.
https://doi.org/10.1111/bjd.12934 DOI: https://doi.org/10.1111/bjd.12934
Saulite I, Ignatova D, Chang Y-T, Fassnacht C, Dimitriou F, Varypataki E, et al. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. Oncoimmunology 2020; 9: 1738797.
https://doi.org/10.1080/2162402X.2020.1738797 DOI: https://doi.org/10.1080/2162402X.2020.1738797
Bosisio FM, Cerroni L. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Am J Dermatopathol 2015; 37: 115-121.
https://doi.org/10.1097/DAD.0000000000000258 DOI: https://doi.org/10.1097/DAD.0000000000000258
Jogdand GM, Mohanty S, Devadas S. Regulators of Tfh cell differentiation. Front Immunol 2016; 7: 520.
https://doi.org/10.3389/fimmu.2016.00520 DOI: https://doi.org/10.3389/fimmu.2016.00520
Gaulard P, de Leval L. Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol 2011; 28: 202-213.
https://doi.org/10.1053/j.semdp.2011.03.003 DOI: https://doi.org/10.1053/j.semdp.2011.03.003
Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood 2017; 129: 1095-1102.
https://doi.org/10.1182/blood-2016-09-692541 DOI: https://doi.org/10.1182/blood-2016-09-692541
Hutloff A. Regulation of T follicular helper cells by ICOS. Oncotarget 2015; 6: 21785-21786.
https://doi.org/10.18632/oncotarget.4798 DOI: https://doi.org/10.18632/oncotarget.4798
Picchio MC, Scala E, Pomponi D, Caprini E, Frontani M, Angelucci I, et al. CXCL13 is highly produced by Sezary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL21 chemokines. Cancer Res 2008; 68: 7137-7146.
https://doi.org/10.1158/0008-5472.CAN-08-0602 DOI: https://doi.org/10.1158/0008-5472.CAN-08-0602
Vergnolle I, Douat-Beyries C, Boulinguez S, Rieu J-B, Vial JP, Baracou R, et al. CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome. Blood 2022; 6: 1813-1825.
https://doi.org/10.1182/bloodadvances.2021005147 DOI: https://doi.org/10.1182/bloodadvances.2021005147
Park J, Daniels J, Wartewig T, G. Ringbloom K. Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. Blood 2021; 138: 1225-1236.
https://doi.org/10.1182/blood.2020009655 DOI: https://doi.org/10.1182/blood.2020009655
Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 2015; 33: 3766-3773.
https://doi.org/10.1200/JCO.2015.61.7142 DOI: https://doi.org/10.1200/JCO.2015.61.7142
Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol 2012; 138: 796-802.
https://doi.org/10.1309/AJCP6DKRND5CKVDD DOI: https://doi.org/10.1309/AJCP6DKRND5CKVDD
Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremnes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21: 3798-3807.
https://doi.org/10.1200/JCO.2003.11.069 DOI: https://doi.org/10.1200/JCO.2003.11.069
Specht E, Kaemmerer D, Sänger J, Wirtz RM, Schulz S, Lupp A. Comparison of immunoreactive score, HER2/ neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms. Histopathology 2015; 67: 368-377.
https://doi.org/10.1111/his.12662 DOI: https://doi.org/10.1111/his.12662
Leclaire Alirkilicarslan A, Dupuy A, Pujals A, Parrens M, Vergier B, Robson A, et al. Expression of TFH markers and detection of RHOA p.G17V and IDH2 p.R172K/S mutations in cutaneous localizations of angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 2017; 41: 1581-1592.
https://doi.org/10.1097/PAS.0000000000000956 DOI: https://doi.org/10.1097/PAS.0000000000000956
Ryu H-J, Kim S-I, Jang H-O, Kim S-H, Oh S-H, Park S, et al. Evaluation of the International Society for Cutaneous Lymphoma Algorithm for the diagnosis of early mycosis fungoides. Cells 2021; 10: 2758.
https://doi.org/10.3390/cells10102758 DOI: https://doi.org/10.3390/cells10102758
Wada DA, Wilcox RA, Harrington SM, Kwon ED, Ansell SM, Comfere NI. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sézary syndrome. Am J Hematol 2011; 86: 325-327.
https://doi.org/10.1002/ajh.21960 DOI: https://doi.org/10.1002/ajh.21960
Roncador G, Verdes-Montenegro J-FG, Tedoldi S, Paterson JC, Klapper W, Ballabio E, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 2007; 92: 1059-1066.
https://doi.org/10.3324/haematol.10864 DOI: https://doi.org/10.3324/haematol.10864
Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116: 767-771.
https://doi.org/10.1182/blood-2009-11-251926 DOI: https://doi.org/10.1182/blood-2009-11-251926
Hawilo A, Zaraa I, Benmously R, Mebazaa A, Osman AB. Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases. Tunis Med 2011; 89: 841-847.
Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol 2012; 51: 1195-1198.
https://doi.org/10.1111/j.1365-4632.2011.05204.x DOI: https://doi.org/10.1111/j.1365-4632.2011.05204.x
Rie MA, Catro I, Lier RAW, Bos JD. Expression of the T-cell activation antigens CD27 and CD28 in normal and psoriatic skin. Clin Exp Dermatol 1996; 21: 104-111.
https://doi.org/10.1111/j.1365-2230.1996.tb00030.x DOI: https://doi.org/10.1111/j.1365-2230.1996.tb00030.x
Liu L, Abken H, Pfohler C, Rappl G, Tilgen W, Reinhold U. Accumulation of CD4+CD7- T cells in inflammatory skin lesions: evidence for preferential adhesion to vascular endothelial cells. Clin Exp Immunol 2000; 121: 94-99.
https://doi.org/10.1046/j.1365-2249.2000.01260.x DOI: https://doi.org/10.1046/j.1365-2249.2000.01260.x
Delfau-Larue MH, Laroche L, Wechsler J, Lepage E, Lahet C, Asso-Bonnet M, et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood 2000; 96: 2987-2992.
https://doi.org/10.1182/blood.V96.9.2987 DOI: https://doi.org/10.1182/blood.V96.9.2987
Diwan AH, Prieto VG, Herling M, Duvic M, Jones D. Primary Sézary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism. Am J Clin Pathol 2005; 123: 510-515.
https://doi.org/10.1309/YB79JG4TMJERQ7PV DOI: https://doi.org/10.1309/YB79JG4TMJERQ7PV
Decroos A, Giustiniani J, Pelletier L, Ingen-Housz-Oro S, Gaulard P, Ortonne N. PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies? Eur J Cancer 2021; 156: 14-15.
https://doi.org/10.1016/S0959-8049(21)00652-3 DOI: https://doi.org/10.1016/S0959-8049(21)00652-3
Published
How to Cite
License
Copyright (c) 2022 Camille Luherne, Sarah Menguy, Thomas Ferte, Marie Beylot-Barry, Julien Seneschal, Brigitte Milpied, Jean-Philippe Vial, Audrey Gros, Samuel Amintas, Béatrice Vergier, Anne Pham-Ledard
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
